K Pharma, Inc.
4896・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 5 directors (including 1 outside director), and all 3 corporate auditors are outside auditors. The Risk and Compliance Committee is held quarterly, and the Board of Directors met 13 times during the fiscal year, with all directors attending every meeting. A Nomination Committee and a Compensation Committee have not been established.
Risk Management
The company holds a Risk and Compliance Committee meeting once every quarter, chaired by the Managing Director and CFO, to build and operate a company-wide risk management and compliance framework. Sustainability-related risks are also identified and assessed by this committee, with a system in place for regular reporting to the Board of Directors. Although events exist that raise material doubt about the company's ability to continue as a going concern, the company has determined that no material uncertainty currently exists.
Shareholder Returns
No annual dividend (¥0) for FY2025 (ending December 2025) and FY2026 (ending December 2026). The company prioritizes retaining internal reserves to secure R&D funding, and continues its no-dividend policy. No share buybacks have been conducted.
Dividend Policy
The company has not paid dividends since its establishment, prioritizing the accumulation of internal reserves for R&D funding. The annual dividend for FY2025 (ending December 2025) is ¥0 (¥0 at second-quarter end, ¥0 at year-end). The forecast for FY2026 (ending December 2026) is also an annual dividend of ¥0 (¥0 at second-quarter end, ¥0 at year-end). If dividends from surplus are paid in the future, the basic policy is a single year-end dividend once per year, with the decision-making body being the general shareholders' meeting. Additionally, under the Articles of Incorporation, an interim dividend by resolution of the Board of Directors is also possible, with the record date set as the end of June each year.
ESG
The company links its business to SDGs Goal 3 ('Good Health and Well-being') and Goal 4 ('Quality Education'), promoting social contribution through research and development in iPS Drug Discovery Platform and regenerative medicine. As a human capital strategy, it has established a specialized discretionary work system and flextime system, focusing on securing diverse specialized talent. Quantitative sustainability-related indicators and targets have not yet been set, with a policy to refine these going forward.
Last updated: March 24, 2026